| NCT02873962 | II | Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor) | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04919629 | II | Recurrent ovarian cancer with symptomatic ascites or pleural effusion | Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion | NY | View Drugs | |
APL-2 | C3-targeted complement inhibitor APL-2 | Blocks the cleavage of C3 | Approved in Other Indications | Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05231122 | II | Recurrent serous, endometrioid or clear cell ovarian cancer | Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer | NY, TX | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | CDX-1140 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03872947 | Ib | Recurrent ovarian cancer | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, LA, NJ, NY, OR, TX, VA, WI | View Drugs | |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|